Browsing by Author "Yiǧitoǧlu R."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Should children with infection be tested for lipid, lipoprotein and apolipoprotein?
    (1998) Işcan A.; Yiǧitoǧlu R.; Onaǧ A.; Vurgun N.; Ari Z.; Ertan P.; Şengil A.Z.
    The lipid profile is known to alter in patients with infection, but there has not been a study of the apolipoprotein levels in serum of otherwise healthy children during infection. Lipids, lipoproteins, apolipoproteins A-1 and B and lipoprotein (a) were evaluated prospectively in 31 consecutive children, aged 4-15 years, who were admitted to the hospital with bacterial pharyngitis. The degree of dyslipidemia associated with bacterial pharyngitis was assessed using each child as his/her own control and by comparison with 79 healthy children who had not had an infection during the past 3 months. Serum total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein A-1 and apolipoprotein B levels were significantly decreased during the symptomatic phase of the disease, whereas the serum triglyceride level was slightly elevated. Serum lipoprotein (a) concentration did not change significantly. In conclusion, it is suggested that serum lipids, lipoproteins and apolipoproteins should not be assessed during infection because of the possible transient changes of these parameters during infection or inflammation.
  • No Thumbnail Available
    Item
    Serum growth hormone and insulin-like growth factor-I levels in fibromyalgia syndrome; [Fi̇bromyalji̇ sendromlu hastalarda serum growth hormon ve insulin-like growth faktör-I düzeyleri̇]
    (2000) Cindaş A.; Tüzün Ç.; Uyanik B.S.; Yiǧitoǧlu R.
    It has been hypothesized that depressed levels of Insulin-Like Growth Factor-I (Somatomedin C) (IGF-I), caused by a deficit of stage-4-sleep-dependent release of Growth Hormone (GH) may play role in pathophysiology and muscle pain in fibromyalgia syndrome (FMS). In this study we aimed to measure the serum levels of GH and IGF-I in patients with FMS and to investigate the relationship between GH and IGF-I levels and clinical features. The study included 32 female patients with FMS and 22 age and sex matched healthy controh. Two way radioimmunoassay method was used to measure serum concentrations of IGF-I and chemiluminans method was used to measure GH. Visual Analog Scale (VAS) was used for subjective assessment of pain and sleep disturbance. Mann-Whitney U test and Pearson Correlation Analysis were used for statistical analysis. The mean serum levels of GH (0,36±0,63 ng/ml in fibromyalgia group and 0,97±1,11 ng/ml in control group) and IGF-I (107.38±25.32 ng/ml in fibromyalgia group and 174.50±41.52 ng/ml in control group) were significantly lower in fibromyalgia group (p<0.001). But there were no statistically significant correlation between sleep disturbance, intensity of general pain, intensity of pain after physical activity, intensity of resting pain, intensity of pain with palpation, intensity of morning stiffness, number of tender points, tender points, tender point palpation scores, Beck Depression Scale scores, Hamilton Depression Rating Scale scores and State Anxiety inventory scores with serum levels of IGF-I and GH. We concluded that the disruption of GH and IGF-I secretion may play role in the pathophysiology of FMS however it does not effect the intensity of clinical findings.